Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Company expands R&D structure of collaboration with Roche Diagnostics
January 6th, 2005
Epigenomics, AG, (ECX), a molecular-diagnostics company developing tests based on DNA methylation, announced that the company has agreed to terms with Roche Diagnostics for an amendment to detail the research & development (R&D) structure of its ongoing collaboration. Under the new terms, the validation process for all candidate tests will be redesigned and expanded. Epigenomics will increase the number of blood or tissue samples to be studied to more than 1000 per test. Each test consists of a panel of DNA methylation biomarkers, substances in the body that may indicate the presence or molecular classification of disease. By increasing the number...
Source: Women's Health Weekly (2005-01-06)
|
